药物审查在应对社区老年患者药物相关问题中的现状

龚辉; 李晨; 单青; 刘伟; 陈孟莉

doi:10.6039/j.issn.1001-0408.2023.02.16

您当前的位置：

首页 >

文章列表页 >

药物审查在应对社区老年患者药物相关问题中的现状

药师与药学服务 | 更新时间：2023-02-22

- 药物审查在应对社区老年患者药物相关问题中的现状
- The status of medication review in addressing drug-related problems of elderly patients in the community
- 中国药房 2023年34卷第2期页码：212-216
- 作者机构：
  
  1.中国人民解放军总医院医疗保障中心药剂科，北京　100853
  2.中国人民解放军总医院研究生院，北京　100853
  3.中国人民解放军总医院医学创新研究部转化医学中心，北京　100853
- 作者简介：
  
  主治医师，硕士。研究方向：临床药学。E-mail：gh2017@yeah.net
  副研究员，博士。研究方向：临床药学、药事管理。E-mail：hellolily301cn@126.com
- 基金信息：
  
  国家重点研发计划项目(2020YFC2005005)
- DOI：10.6039/j.issn.1001-0408.2023.02.16
  中图分类号： R969.3
- 纸质出版日期：2023-01-30，
  
  收稿日期：2022-10-05，
  
  修回日期：2022-12-27，
扫描看全文
龚辉,李晨,单青等.药物审查在应对社区老年患者药物相关问题中的现状 ^Δ[J].中国药房,2023,34(02):212-216.

GONG Hui,LI Chen,SHAN Qing,et al.The status of medication review in addressing drug-related problems of elderly patients in the community[J].ZHONGGUO YAOFANG,2023,34(02):212-216.
龚辉,李晨,单青等.药物审查在应对社区老年患者药物相关问题中的现状 ^Δ[J].中国药房,2023,34(02):212-216. DOI： 10.6039/j.issn.1001-0408.2023.02.16.

GONG Hui,LI Chen,SHAN Qing,et al.The status of medication review in addressing drug-related problems of elderly patients in the community[J].ZHONGGUO YAOFANG,2023,34(02):212-216. DOI： 10.6039/j.issn.1001-0408.2023.02.16.

摘要

随着我国人口老龄化日益加剧，社区老年患者药物相关问题的发生率也逐渐增加。药物相关问题会导致社区老年患者跌倒、衰弱等不良健康结局的发生率增加。药物审查是应对药物相关问题的有效手段之一。欧美国家应对药物相关问题的药物审查模式已发展数十年，其中，英国的药物审查模式更注重社区养老机构老年患者的药物治疗管理，而美国与澳大利亚的药物审查模式的覆盖范围更为广泛（包含所有社区老年患者），药物审查频率也更为明确和规范。与上述国家相比，我国的药物审查模式建设起步较晚。我国可借鉴英、美、澳等国的先进经验，积极探索构建适宜我国国情的药物审查模式，以提高社区老年患者健康水平、节约社会公共医疗资源。

Abstract

With the increasing aging of our population， the incidence of drug-related problems among elderly patients in the community is gradually increasing. Drug-related problems can lead to an increased incidence of adverse health outcomes such as falls and frailty in elderly patients in the community. Medication review is one of the effective means of addressing drug-related problems. The medication review models in Europe and the United States have been developed for decades to address drug-related problems； medication review model in the United Kingdom focuses on the management of drug therapy for elderly patients in aged care facilities， while the medication review models in the United States and Australia have a broader scope（covering all elderly patients in the community）， and the frequency of medication reviews in the United States and Australia are clearer and more standardized. Compared with the above countries， China’s medication review model has a late start. Our country can learn from the advanced experience of the United Kingdom， the United States， Australia and other countries， actively explore and build a drug review model suitable for China’s national conditions， so as to improve the health level of elderly patients in the community and save social public medical resources.

关键词

药物审查老年人药物相关问题

Keywords

elderlydrug-related problems

references

FANG E F，SCHEIBYE-KNUDSEN M，JAHN H J，et al. A research agenda for aging in China in the 21st century（2nd edition）：focusing on basic and translational research，long-term care，policy and social networks[J]. Ageing Res Rev，2020，64：101174.

MIDÃO L，GIARDINI A，MENDITTO E，et al. Polypharmacy prevalence among older adults based on the survey of health，ageing and retirement in Europe[J]. Arch Gerontol Geriatr，2018，78：213-220.

KLOTZ U. Pharmacokinetics and drug metabolism in the elderly[J]. Drug Metab Rev，2009，41（2）：67-76.

Phrmaceutical Care Network Europe Association. Classification for drug related problems[EB/OL].（2020-10-05）[2022-07-05]. https：//www.pcne.org/upload/files/417_PCNE_ classification_V9-1_final.pdfhttps://www.pcne.org/upload/files/417_PCNE_classification_V9-1_final.pdf.

PLÁCIDO A I，HERDEIRO M T，MORGADO M，et al. Drug-related problems in home-dwelling older adults：a systematic review[J]. Clin Ther，2020，42（4）：559-572.

YANG J D，MENG L，LIU Y，et al. Drug-related problems among community-dwelling older adults in mainland China[J]. Int J Clin Pharm，2018，40（2）：368-375.

LAU E C Y，et al. Prevalence and risk factors for drug-related problems in people with dementia living in the community：a systematic review and meta-analysis[J]. J Am Med Dir Assoc，2022，23（6）：980-991.

张莎，王婧，祝德秋. 社区老年慢病患者药物相关问题评估及影响因素分析[J]. 中南药学，2020，18（6）：1046-1051.

WUCHERER D，THYRIAN J R，EICHLER T，et al. Drug-related problems in community-dwelling primary care patients screened positive for dementia[J]. Int Psychogeriatr，2017，29（11）：1857-1868.

LENANDER C，BONDESSON Å，VIBERG N，et al. Effects of medication reviews on use of potentially inappropriate medications in elderly patients：a cross-sectional study in Swedish primary care[J]. BMC Health Serv Res，2018，18（1）：616.

ANG F Z，PAU J E，KOH E W，et al. Drug-related problems associated with community-dwelling older persons living alone in Singapore[J]. Int J Clin Pharm，2019，41（3）：719-727.

SILVA C，RAMALHO C，LUZ I，et al. Drug-related problems in institutionalized，polymedicated elderly patients：opportunities for pharmacist intervention[J]. Int J Clin Pharm，2015，37（2）：327-334.

OHARA E，BANDO Y，YOSHIDA T，et al. Central nervous system agent classes and fragility fracture risk among elderly Japanese individuals in a nationwide case-crossover design study[J]. Biol Pharm Bull，2020，43（2）：340-347.

REALLON E，CHAVENT B，GERVAIS F，et al. Medication exposure and frailty in older community-dwelling patients：a cross-sectional study[J]. Int J Clin Pharm，2020，42（2）：508-514.

LEWIS J R，BARRE D，ZHU K，et al. Long-term proton pump inhibitor therapy and Falls and fractures in elderly women：a prospective cohort study[J]. J Bone Miner Res，2014，29（11）：2489-2497.

GOMM W，VON HOLT K，THOMÉ F，et al. Association of proton pump inhibitors with risk of dementia：a pharmacoepidemiological claims data analysis[J]. JAMA Neurol，2016，73（4）：410-416.

PONTE MÁRQUEZ P H，TORRES O H，SAN-JOSÉ A，et al. Potentially inappropriate antihypertensive prescriptions to elderly patients：results of a prospective，observational study[J]. Drugs Aging，2017，34（6）：453-466.

GRIESE-MAMMEN N，HERSBERGER K E，MESSERLI M，et al. PCNE definition of medication review：reaching agreement[J]. Int J Clin Pharm，2018，40（5）：1199-1208.

PSA. Guidelines for comprehensive medication management reviews[EB/OL].[2022-10-17].https：//www.ppaonline.com.au/wp-content/uploads/2020/04/PSA-Guidelines-for-Comprehensive-Medication-Management-Reviews.pdfhttps://www.ppaonline.com.au/wp-content/uploads/2020/04/PSA-Guidelines-for-Comprehensive-Medication-Management-Reviews.pdf.

CMS. CY 2020 medication therapy management program guidance and submission instructions[EB/OL].（2020-09-01）[2022-07-05].https：//www.cms.gov/Medicare/Prescri-ption-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Memo-Contract-Year-2020-Medication-Therapy-Management-MTM-Program-Submission-v-041019-.pdfhttps://www.cms.gov/Medicare/Prescri-ption-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Memo-Contract-Year-2020-Medication-Therapy-Management-MTM-Program-Submission-v-041019-.pdf.

CMS. State operations manual appendix PP：guidance to surveyors for long term care facilities[EB/OL].（2020-08-01）[2022-07-05].https：//www.cms.gov/Medicare/Provider- Enrollment-and-Certification/GuidanceforLawsAndRegulations/Downloads/Appendix-PP-State-Operations-Manual. pdfhttps://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/GuidanceforLawsAndRegulations/Downloads/Appendix-PP-State-Operations-Manual.pdf.

BROWN C H. The consultant pharmacist’s role in long-term care facilities[J]. J Pharm Pract，1988，1（3）：166-172.

SIMONSON W. Significant changes in CMS pharmacy services F-Tags for long-term care facilities[J]. Geriatr Nurs，2018，39（1）：112-114.

CMS. Medicare part D medication therapy management（MTM）programs：fact sheet[EB/OL].[2022-07-05].https：//www.cms.gov/Medicare/Prescription-Drug-Coverage/ PrescriptionDrugCovContra/Downloads/CY2019-MTM-Fact-Sheet.pdfhttps://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/CY2019-MTM-Fact-Sheet.pdf.

NHS. Five year forward view[EB/OL].[2022-07-05].https：//www.england.nhs.uk/wp-content/uploads/2014/10/5yfv-web.pdfhttps://www.england.nhs.uk/wp-content/uploads/2014/10/5yfv-web.pdf.

NHS. Medicines optimisation in care homes [EB/OL].[2022-07-05].https：//www.england.nhs.uk/wp-content/uploads/2018/03/medicines-optimisation-in-care-homes-pro- gramme-overview.pdfhttps://www.england.nhs.uk/wp-content/uploads/2018/03/medicines-optimisation-in-care-homes-pro-gramme-overview.pdf.

Australia Government Department of Health and Aged Care. Residential medication management review[EB/OL].[2022-07-25]. https：//www.ppaonline.com.au/wp-content/uploads/2020/04/RMMR-Program-Rules-COVID-19.pdfhttps://www.ppaonline.com.au/wp-content/uploads/2020/04/RMMR-Program-Rules-COVID-19.pdf.

PSA. Guidelines for quality use of medicines（QUM） services[EB/OL].[2022-07-05].https：//www.ppaonline.com.au/wp-content/uploads/2020/04/PSA-Guidelines-for-Quality- Use-of-Medicines-QUM-services.pdfhttps://www.ppaonline.com.au/wp-content/uploads/2020/04/PSA-Guidelines-for-Quality-Use-of-Medicines-QUM-services.pdf.

PSA. Guidelines for pharmacists providing residential medication management review（RMMR） and quality use of medicines（QUM） services[EB/OL].[2022-07-05].https：//www.ppaonline.com.au/wp-content/uploads/2019/01/PSA-RMMR-and-QUM-Guidelines.pdfhttps://www.ppaonline.com.au/wp-content/uploads/2019/01/PSA-RMMR-and-QUM-Guidelines.pdf.

Australia Government Department of Health and Aged Care. Program rules quality use of medicines[EB/OL].[2022-07-05].https：//www.ppaonline.com.au/wp-content/uploads/2020/04/QUM-Program-Rules-COVID-19. pdfhttps://www.ppaonline.com.au/wp-content/uploads/2020/04/QUM-Program-Rules-COVID-19.pdf.

MCCAHON D，DENHOLM R E，HUNTLEY A L，et al. Development of a model of medication review for use in clinical practice：Bristol medication review model[J]. BMC Med，2021，19（1）：262.

GARLAND C T，GUÉNETTE L，KRÖGER E，et al. A new care model reduces polypharmacy and potentially inappropriate medications in long-term care[J]. J Am Med Dir Assoc，2021，22（1）：141-147.

THIRUCHELVAM K，HASAN S S，PUDMENZKY A，et al. Development，validation and evaluation of an online medication review tool（MedReview）[J]. PLoS One，2022，17（6）：e0269322.

TASAI S，KUMPAT N，DILOKTHORNSAKUL P，et al. Impact of medication reviews delivered by community pharmacist to elderly patients on polypharmacy：a meta-analysis of randomized controlled trials[J]. J Patient Saf，2021，17（4）：290-298.

SCHINDLER E，HOHMANN C，CULMSEE C. Medication review by community pharmacists for type 2 diabetes patients in routine care：results of the DIATHEM-study[J]. Front Pharmacol，2020，11：1176.

ROSLI M R，NEOH C F，WU D B，et al. Evaluation of home medication review for patients with type 2 diabetes mellitus by community pharmacists：a randomised controlled trial[J]. Pharm Pract（Granada），2021，19（3）：2397.

ROSLI M R，WU D B C，NEOH C F，et al. Economic evaluation of home medication review by community pharmacists（HMR-CP）for patients with type 2 diabetes mellitus（T2DM）[J]. J Med Econ，2021，24（1）：730-740.

KARI H N，ÄIJÖ-JENSEN N，KORTEJÄRVI H，et al. Effectiveness and cost-effectiveness of a people-centred care model for community-living older people versus usual care：a randomised controlled trial[J]. Res Social Adm Pharm，2022，18（6）：3004-3012.

SALARI P，O’MAHONY C，HENRARD S，et al. Cost-effectiveness of a structured medication review approach for multimorbid older adults：within-trial analysis of the OPERAM study[J]. PLoS One，2022，17（4）：e0265507.

刘清扬，白向荣，王可，等. 门诊和居家患者药物相关问题分类系统的研制[J]. 药物不良反应杂志，2021，23（3）：120-127.

上海市医院协会临床药事管理专业委员会，上海市药学会医院药学专业委员会，廖赟，等. 《中国药物相关问题分类系统（V1.0）》使用标准[J]. 中华预防医学杂志，2022，56（8）：1042-1049.

刘思彤，杨丽娟，李全志，等. 老年高血压患者健康管理软件需求调研[J]. 中国医院药学杂志，2022，42（5）：560-563.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

药学服务中药物相关问题的研究进展